Leucine-restricted diet for gastric cancer patients
Part of Cancer, Digestive system clinical trials.
This trial tests if a diet low in leucine (an amino acid) can help treat gastric cancer before surgery. It aims to see if it's safe and effective for patients who are preparing for tumor removal.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with stomach cancer and need endoscopic marking or tumor mapping before surgery.
- You are between 18 and 70 years old.
- You can eat food or take liquid feed through a tube in your nose or stomach.
- You have signed a consent form and agree to join the study.
- Your cancer has not spread to other parts of the body (scans show no distant spread), and surgery is possible.
- You do not have another active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special diet low in leucine (an amino acid) combined with chemotherapy and immunotherapy drugs can help treat locally advanced gastric cancer before surgery. The goal is to see if this combination is safe and more effective than standard treatment alone.
This trial studies whether intensive dietary education (diet coaching) after gastrectomy can improve patients’ nutrition and recovery. It is for people with early-stage primary stomach cancer who have no spread to distant organs.
This trial studies whether doing a structured exercise program and receiving enteral (tube) nutrition after gastric cancer surgery can improve survival. It focuses on people with stage Ib to stage IIIc stomach cancer who have had standard surgery and have not had chemo or radiation before.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests combining chemotherapy (SOX), an immunotherapy drug (tislelizumab), and low-dose radiation before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination shrinks tumors more effectively.
This trial tests a combination of two targeted drugs (Envafolimab and Fruquintinib) plus chemotherapy given before surgery for certain types of stomach cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.